An Illinois startup has developed AI-powered imaging technology for breast cancer surgery, creating 3D tumour models from MRIs to aid surgical planning. The FDA-cleared technology provides colour-coded visualisations and key measurements, helping surgeons decide between breast conservation and mastectomy. The company is also developing AI to convert patient positioning in images and quickly assess cancer recurrence risk, potentially reducing treatment planning time significantly.

**For healthcare providers and hospitals:** This AI-powered imaging technology could revolutionize breast cancer surgery planning. You'll likely see improved surgical outcomes, reduced operating times, and potentially lower costs. Consider how this might affect your patient care protocols and staff training needs. **For medical imaging companies:** Prepare for increased competition in the breast cancer imaging market. You may need to invest in AI capabilities or form strategic partnerships to stay competitive. **For health insurers:** This technology could lead to more precise surgeries, potentially reducing complications and readmissions. You might consider adjusting coverage policies to incentivize the use of such AI-assisted planning tools.

Expect rapid advancements in AI-assisted surgical planning across various cancer types and medical specialties. You'll likely see increased integration of AI with robotics in surgical suites, potentially changing the skill sets required for surgeons and support staff. As AI becomes more prevalent in treatment planning, you may need to re-evaluate your data management and cybersecurity strategies to handle the increased flow of sensitive medical information. Watch for potential regulatory changes as the FDA and other bodies adapt to the growing role of AI in healthcare decision-making. Consider how your organization can proactively adapt to these changes, perhaps by establishing an AI strategy team or partnering with tech-savvy healthcare startups.